PRRX1 and gastric cancer: The abrogation of PHOX1’s tumor-promoting effects by either NGFR knockdown or ERK1/2 inhibition provides compelling evidence for the functional importance of the PHOX1-NGFR-ERK1/2 signaling axis in GC progression.